Orthofix Medical Inc. (OFIX)
| Market Cap | 485.46M -8.2% |
| Revenue (ttm) | 825.37M +2.6% |
| Net Income | -60.01M |
| EPS | -1.51 |
| Shares Out | 40.42M |
| PE Ratio | n/a |
| Forward PE | 11.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,526 |
| Open | 12.17 |
| Previous Close | 12.29 |
| Day's Range | 11.82 - 12.17 |
| 52-Week Range | 10.24 - 16.99 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 17.25 (+43.63%) |
| Earnings Date | May 5, 2026 |
About OFIX
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graf... [Read more]
Financial Performance
In 2025, Orthofix Medical's revenue was $822.31 million, an increase of 2.85% compared to the previous year's $799.49 million. Losses were -$92.19 million, -26.83% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for OFIX stock is "Buy." The 12-month stock price target is $17.25, which is an increase of 43.63% from the latest price.
News
Orthofix announces FITBONE innovation at POSNA 2026 meeting
Orthofix (OFIX) Medical announced new pediatric limb reconstruction innovations that expand treatment options for pediatric and small stature patients. The Company will highlight these advances at the...
Orthofix Expands Pediatric Limb Reconstruction Portfolio with New FITBONE™ Innovation at POSNA 2026 Annual Meeting
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced new pediatric limb reconstruction innovations that expand treatmen...
Halper Sadeh LLC Encourages Orthofix Medical Inc. Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Shareholders are encouraged to contact the firm at no cost or obligation.
Orthofix Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 3% net sales growth, margin expansion, and strong execution, with top distributor partners driving significant gains. Guidance for 2026 is reaffirmed, expecting accelerating growth and margin improvement, supported by innovation and operational discipline.
Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, r...
Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
Orthofix to Report First Quarter 2026 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2026 financial results on T...
Orthofix announces spine leadership realignment
Orthofix (OFIX) has streamlined its Spine organization by eliminating the role of President, Global Spine Solutions. As a result, key Spine leaders will now report directly to Orthofix Chief Executive...
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced a strategic realignment of its Spine leadership team designed to a...
Orthofix price target lowered to $18 from $22 at Stifel
Stifel lowered the firm’s price target on Orthofix (OFIX) to $18 from $22 and keeps a Buy rating on the shares. The firm updated models across its medical technology and…
Orthofix Medical Transcript: TD Cowen 46th Annual Health Care Conference
Leadership transformation and commercial realignment have driven margin expansion and set the stage for multi-year growth, with over a dozen product launches and a focus on high-value segments. Financial targets include 6.5%-7.5% sales CAGR and mid-teens EBITDA margin by 2028.
Orthofix Medical Transcript: 2026 CG Musculoskeletal Conference
Strong operational progress and financial discipline led to growth across all segments, with channel optimization and innovation driving future momentum. U.S. limb reconstruction is a major growth focus, while 7D technology and biologics see renewed investment. Long-range goals were extended to 2028 to fully realize channel upgrades.
Orthofix price target lowered to $20 from $24 at Canaccord
Canaccord lowered the firm’s price target on Orthofix (OFIX) to $20 from $24 and keeps a Buy rating on the shares. The firm updated its model to reflect Q4 results…
Orthofix price target lowered to $17 from $18 at Barrington
Barrington lowered the firm’s price target on Orthofix (OFIX) to $17 from $18 and keeps an Outperform rating on the shares. The company reported solid Q4 results but its longer…
Orthofix Medical Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year growth in BGT, limb reconstruction, and spine, with margin expansion and robust free cash flow. 2026 guidance calls for 5.5% sales growth, higher EBITDA, and positive free cash flow, supported by new product launches and a strengthened distributor network.
Orthofix reports Q4 EPS (6c) vs. (75c) last year
Reports Q4 revenue $219.91M, consensus $218.71M. “The fourth quarter capped a year of meaningful operational progress for Orthofix (OFIX),” said Massimo Calafiore, president and CEO. “Throughout 2025,...
Orthofix reports Q4 EPS (6c) vs. (75c) last year
Reports Q4 revenue $219.91M, consensus $218.71M. “The fourth quarter capped a year of meaningful operational progress for Orthofix (OFIX),” said Massimo Calafiore, president and CEO. “Throughout 2025,...
Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended De...
Orthofix to Participate in Upcoming Investor Conferences
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and...
Orthofix to Report Fourth Quarter and Full-Year 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2025 financi...
Orthofix initiated with a Hold at TD Cowen
TD Cowen initiated coverage of Orthofix (OFIX) with a Hold rating and $14 price target The company is affecting enterprise-wide change while driving improving profitability and cash flow, even though…
Orthofix Medical Transcript: Stifel 2025 Healthcare Conference
Q3 results exceeded expectations with strong U.S. spine and orthopedics growth, driven by innovation, distributor consolidation, and new product launches. Margin expansion initiatives and a robust product pipeline, including Virata, position the business for accelerated growth and profitability through 2027.
Orthofix Medical Transcript: UBS Global Healthcare Conference 2025
The company has transformed its financial base, achieved sustained EBITDA growth, and is launching innovative products like Vertabra and TruLock Elevate. Strategic distributor consolidation, disciplined R&D, and a focus on high-margin markets support long-term growth targets.
Orthofix price target raised to $18 from $17 at Barrington
Barrington analyst Michael Petusky raised the firm’s price target on Orthofix (OFIX) to $18 from $17 and keeps an Outperform rating on the shares. The company reported strong Q3 results…
Orthofix Medical Earnings Call Transcript: Q3 2025
Strong Q3 results featured 6% revenue growth, margin expansion, and robust U.S. spine and orthopedics performance. Guidance for 2025 was narrowed with higher EBITDA expectations, and new product launches and distributor strategies are set to drive future growth.